Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications

Autor:	Simcha Therapeutics
Zdroj:	Business Wire (English). 01/08/2024.
Abstrakt:	Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced that it has entered into a license and option agreement with Janssen Biotech, Inc. (“Janssen”), a Johnson & Johnson company, where Janssen will work to armor select CAR T-based cell therapy candidates with Simcha’s novel proprietary decoy-resistant IL-18 (DR-18). The agreement was facilitated by Johnson & Johnson Innovation. [ABSTRACT FROM PUBLISHER]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.